Article in Addiction biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Roberta G AnversaFlorey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, The University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0003-1510-880X
Linh TranSchool of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia.
Andrew A BolingerCenter for Addiction Sciences and Therapeutics, and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA.
Jia ZhouCenter for Addiction Sciences and Therapeutics, and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA.ORCID 0000-0002-2811-1090
Kathryn A CunninghamCenter for Addiction Sciences and Therapeutics, and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas, USA.
Andrew J LawrenceFlorey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, The University of Melbourne, Parkville, VIC, Australia.ORCID 0000-0001-6836-727X
Erin J CampbellSchool of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Callaghan, NSW, Australia.ORCID 0000-0002-4722-6897
Funding
5-HT2 Receptor Allosterism in Cocaine Use DisorderR01DA038446 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Kathryn A. Cunningham, Jia Zhou · 2015 to 2026
$5.3M
Core Center for Translational Addiction SciencesP30DA028821 · NIDA · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A. · 2009 to 2010
$1.5M
Optimization of Allosteric Modulators of 5-HT2C ReceptorR21MH093844 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI CUNNINGHAM, KATHRYN A., ZHOU, JIA · 2012 to 2013
$450k
Australian Research Council DE230100401Brain and Behavior Research Foundation 32829Center for Addiction Sciences and Therapeutics at UTMBChauncey Leake Distinguished Professor EndowmentEdith & Robert Zinn Chair in Drug Discovery Endowment FundHunter Medical Research InstituteJohn D. Stobo, M.D. Distinguished Chair Endowment FundNational Health and Medical Research Council 2009851NIDA NIH HHS P30 DA028821NIDA NIH HHS R01 DA038446NIH HHS P30 DA028821NIH HHS R01 DA038446NIH HHS R21 MH093844NIMH NIH HHS R21 MH093844
6 · The paper itself
Abstract
Alcohol misuse remains a leading cause of preventable death worldwide, prompting research into novel pharmacotherapies for alcohol use disorder (AUD). This study investigated the therapeutic potential of full agonism or positive allosteric modulation of the serotonin 2C receptor (5-HT
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.